S&P 500   3,329.46 (+0.12%)
DOW   29,265.29 (+0.36%)
QQQ   225.63 (+0.46%)
AAPL   321.34 (+0.66%)
FB   221.25 (+0.68%)
MSFT   167.27 (+0.33%)
GOOGL   1,491.96 (+0.49%)
AMZN   1,891.63 (+0.37%)
CGC   24.79 (+0.94%)
NVDA   256.30 (+1.36%)
BABA   218.71 (-0.19%)
MU   59.73 (+0.90%)
GE   11.72 (-0.42%)
TSLA   567.49 (-0.82%)
AMD   52.31 (+1.16%)
T   38.56 (-0.18%)
ACB   2.07 (+0.00%)
F   9.06 (-0.87%)
NFLX   353.91 (+1.23%)
PRI   125.37 (-0.14%)
BAC   33.94 (-0.53%)
DIS   141.70 (-0.35%)
GILD   63.85 (-0.14%)
S&P 500   3,329.46 (+0.12%)
DOW   29,265.29 (+0.36%)
QQQ   225.63 (+0.46%)
AAPL   321.34 (+0.66%)
FB   221.25 (+0.68%)
MSFT   167.27 (+0.33%)
GOOGL   1,491.96 (+0.49%)
AMZN   1,891.63 (+0.37%)
CGC   24.79 (+0.94%)
NVDA   256.30 (+1.36%)
BABA   218.71 (-0.19%)
MU   59.73 (+0.90%)
GE   11.72 (-0.42%)
TSLA   567.49 (-0.82%)
AMD   52.31 (+1.16%)
T   38.56 (-0.18%)
ACB   2.07 (+0.00%)
F   9.06 (-0.87%)
NFLX   353.91 (+1.23%)
PRI   125.37 (-0.14%)
BAC   33.94 (-0.53%)
DIS   141.70 (-0.35%)
GILD   63.85 (-0.14%)
S&P 500   3,329.46 (+0.12%)
DOW   29,265.29 (+0.36%)
QQQ   225.63 (+0.46%)
AAPL   321.34 (+0.66%)
FB   221.25 (+0.68%)
MSFT   167.27 (+0.33%)
GOOGL   1,491.96 (+0.49%)
AMZN   1,891.63 (+0.37%)
CGC   24.79 (+0.94%)
NVDA   256.30 (+1.36%)
BABA   218.71 (-0.19%)
MU   59.73 (+0.90%)
GE   11.72 (-0.42%)
TSLA   567.49 (-0.82%)
AMD   52.31 (+1.16%)
T   38.56 (-0.18%)
ACB   2.07 (+0.00%)
F   9.06 (-0.87%)
NFLX   353.91 (+1.23%)
PRI   125.37 (-0.14%)
BAC   33.94 (-0.53%)
DIS   141.70 (-0.35%)
GILD   63.85 (-0.14%)
S&P 500   3,329.46 (+0.12%)
DOW   29,265.29 (+0.36%)
QQQ   225.63 (+0.46%)
AAPL   321.34 (+0.66%)
FB   221.25 (+0.68%)
MSFT   167.27 (+0.33%)
GOOGL   1,491.96 (+0.49%)
AMZN   1,891.63 (+0.37%)
CGC   24.79 (+0.94%)
NVDA   256.30 (+1.36%)
BABA   218.71 (-0.19%)
MU   59.73 (+0.90%)
GE   11.72 (-0.42%)
TSLA   567.49 (-0.82%)
AMD   52.31 (+1.16%)
T   38.56 (-0.18%)
ACB   2.07 (+0.00%)
F   9.06 (-0.87%)
NFLX   353.91 (+1.23%)
PRI   125.37 (-0.14%)
BAC   33.94 (-0.53%)
DIS   141.70 (-0.35%)
GILD   63.85 (-0.14%)
Log in

NASDAQ:EXEL - Exelixis Stock Price, Forecast & News

$19.23
-0.34 (-1.74 %)
(As of 01/24/2020 09:43 AM ET)
Today's Range
$19.14
Now: $19.23
$19.80
50-Day Range
$16.89
MA: $18.35
$20.44
52-Week Range
$15.02
Now: $19.23
$25.31
Volume142,477 shs
Average Volume3.08 million shs
Market Capitalization$5.84 billion
P/E Ratio9.86
Dividend YieldN/A
Beta1.74
Exelixis, Inc, an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of patients with progressive and metastatic medullary thyroid cancer. Read More…

Industry, Sector and Symbol

Industry Commercial physical research
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:EXEL
CUSIP30161Q10
Phone650-837-7000

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$853.83 million
Cash Flow$1.48 per share
Book Value$4.31 per share

Profitability

Net Income$690.07 million

Miscellaneous

Employees484
Market Cap$5.84 billion
Next Earnings Date2/26/2020 (Confirmed)
OptionableOptionable

Receive EXEL News and Ratings via Email

Sign-up to receive the latest news and ratings for EXEL and its competitors with MarketBeat's FREE daily newsletter.


(Ad)

Paul Mampilly correctly predicted every bull and bear market over the last two decades. He made millions. His new "Dow 100,000" prediction is his boldest yet. Even more stunning... Paul reveals how you could make millions as it unfolds.

Exelixis (NASDAQ:EXEL) Frequently Asked Questions

What is Exelixis' stock symbol?

Exelixis trades on the NASDAQ under the ticker symbol "EXEL."

How were Exelixis' earnings last quarter?

Exelixis, Inc. (NASDAQ:EXEL) posted its quarterly earnings data on Wednesday, October, 30th. The biotechnology company reported $0.31 earnings per share for the quarter, beating the Zacks' consensus estimate of $0.19 by $0.12. The biotechnology company had revenue of $271.70 million for the quarter, compared to analysts' expectations of $228.17 million. Exelixis had a net margin of 64.05% and a return on equity of 25.55%. The business's revenue was up 20.5% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.44 earnings per share. View Exelixis' Earnings History.

When is Exelixis' next earnings date?

Exelixis is scheduled to release their next quarterly earnings announcement on Wednesday, February 26th 2020. View Earnings Estimates for Exelixis.

What price target have analysts set for EXEL?

11 analysts have issued 12-month target prices for Exelixis' stock. Their forecasts range from $19.00 to $35.00. On average, they anticipate Exelixis' stock price to reach $26.50 in the next year. This suggests a possible upside of 35.4% from the stock's current price. View Analyst Price Targets for Exelixis.

What is the consensus analysts' recommendation for Exelixis?

11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Exelixis in the last year. There are currently 3 hold ratings and 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Exelixis.

Has Exelixis been receiving favorable news coverage?

Media coverage about EXEL stock has been trending very positive on Friday, according to InfoTrie Sentiment. InfoTrie scores the sentiment of news coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Exelixis earned a coverage optimism score of 3.9 on InfoTrie's scale. They also assigned media stories about the biotechnology company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an effect on the company's share price in the near term. View News Stories for Exelixis.

Are investors shorting Exelixis?

Exelixis saw a increase in short interest in December. As of December 31st, there was short interest totalling 18,100,000 shares, an increase of 17.0% from the December 15th total of 15,470,000 shares. Based on an average daily trading volume, of 2,910,000 shares, the days-to-cover ratio is presently 6.2 days. Approximately 6.2% of the company's shares are sold short. View Exelixis' Current Options Chain.

Who are some of Exelixis' key competitors?

What other stocks do shareholders of Exelixis own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Exelixis investors own include Micron Technology (MU), NVIDIA (NVDA), Advanced Micro Devices (AMD), Alibaba Group (BABA), Gilead Sciences (GILD), Incyte (INCY), Intel (INTC), BioMarin Pharmaceutical (BMRN), Corbus Pharmaceuticals (CRBP) and Puma Biotechnology (PBYI).

Who are Exelixis' key executives?

Exelixis' management team includes the folowing people:
  • Dr. Stelios Papadopoulos, Co-Founder & Chairman (Age 71)
  • Dr. Michael M. Morrissey, CEO, Pres & Director (Age 58)
  • Mr. Christopher J. Senner, Exec. VP & CFO (Age 51)
  • Dr. Peter Lamb, Exec. VP of Scientific Strategy & Chief Scientific Officer (Age 58)
  • Mr. Jeffrey J. Hessekiel, Exec. VP, Gen. Counsel & Sec. (Age 50)

Who are Exelixis' major shareholders?

Exelixis' stock is owned by a variety of of retail and institutional investors. Top institutional investors include Chicago Capital LLC (0.27%), Tealwood Asset Management Inc. (0.04%), Louisiana State Employees Retirement System (0.02%), Assenagon Asset Management S.A. (0.02%), State of Alaska Department of Revenue (0.02%) and Zurcher Kantonalbank Zurich Cantonalbank (0.01%). Company insiders that own Exelixis stock include Alan M Garber, Carl B Feldbaum, Charles Cohen, Christopher J Senner, George A Scangos, George Poste, Gisela Schwab, Jeffrey Hessekiel, Lance Willsey, Michael Morrissey, Patrick J Haley, Peter Lamb, Stelios Papadopoulos and Vincent T Marchesi. View Institutional Ownership Trends for Exelixis.

Which institutional investors are selling Exelixis stock?

EXEL stock was sold by a variety of institutional investors in the last quarter, including Tealwood Asset Management Inc., State of Alaska Department of Revenue, Sonora Investment Management LLC and Patriot Financial Group Insurance Agency LLC. Company insiders that have sold Exelixis company stock in the last year include Alan M Garber, Carl B Feldbaum, Charles Cohen, Christopher J Senner, George A Scangos, George Poste, Gisela Schwab, Jeffrey Hessekiel, Lance Willsey, Michael Morrissey, Patrick J Haley, Peter Lamb and Vincent T Marchesi. View Insider Buying and Selling for Exelixis.

Which institutional investors are buying Exelixis stock?

EXEL stock was purchased by a variety of institutional investors in the last quarter, including Assenagon Asset Management S.A., Ballentine Partners LLC, Alpine Global Management LLC, Chicago Capital LLC, Nisa Investment Advisors LLC, Huntington National Bank, Manchester Financial Inc. and Zurcher Kantonalbank Zurich Cantonalbank . View Insider Buying and Selling for Exelixis.

How do I buy shares of Exelixis?

Shares of EXEL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Exelixis' stock price today?

One share of EXEL stock can currently be purchased for approximately $19.57.

How big of a company is Exelixis?

Exelixis has a market capitalization of $5.95 billion and generates $853.83 million in revenue each year. The biotechnology company earns $690.07 million in net income (profit) each year or $1.43 on an earnings per share basis. Exelixis employs 484 workers across the globe.View Additional Information About Exelixis.

What is Exelixis' official website?

The official website for Exelixis is http://www.exelixis.com/.

How can I contact Exelixis?

Exelixis' mailing address is 1851 Harbor Bay Parkway, Alameda CA, 94502. The biotechnology company can be reached via phone at 650-837-7000 or via email at [email protected]


MarketBeat Community Rating for Exelixis (NASDAQ EXEL)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  455 (Vote Outperform)
Underperform Votes:  412 (Vote Underperform)
Total Votes:  867
MarketBeat's community ratings are surveys of what our community members think about Exelixis and other stocks. Vote "Outperform" if you believe EXEL will outperform the S&P 500 over the long term. Vote "Underperform" if you believe EXEL will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/24/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel